CASI - CASI Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
2,787
0
0
0
Cost of Revenue
-
-
-
0
Gross Profit
-
-
-
0
Operating Expenses
Research Development
10,697
8,507
7,595
4,646
Selling General and Administrative
27,391
17,997
3,156
4,775
Total Operating Expenses
38,088
26,504
10,751
9,421
Operating Income or Loss
-37,949
-26,504
-10,751
-9,421
Interest Expense
-
8
15
34
Total Other Income/Expenses Net
-5,188
-1,007
-20
-7
Income Before Tax
-43,851
-27,472
-10,770
-9,453
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-43,851
-27,472
-10,770
-9,453
Net Income
-42,345
-27,472
-10,770
-9,453
Net Income available to common shareholders
-42,398
-27,472
-10,770
-9,453
Reported EPS
Basic
-
-0.32
-0.18
-0.17
Diluted
-
-0.32
-0.18
-0.17
Weighted average shares outstanding
Basic
-
84,752
61,514
55,869
Diluted
-
84,752
61,514
55,869
EBITDA
-
-25,792
-10,637
-9,353